European Union - English - EMA (European Medicines Agency)

novartis europharm limited  - voretigene neparvovec - leber congenital amaurosis; retinitis pigmentosa - other ophthalmologicals - luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic rpe65 mutations and who have sufficient viable retinal cells.

Canada - English - Health Canada

novartis pharmaceuticals canada inc - voretigene neparvovec - solution - 5000000000000vg - voretigene neparvovec 5000000000000vg - cellular and gene therapy

Israel - English - Ministry of Health

novartis israel ltd - voretigene neparvovec - concentrate and solvent for solution for injection - voretigene neparvovec 5x10^12 vector genomes/ml - luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic rpe65 mutations and who have sufficient viable retinal cells.